Industry

SAN FRANCISCO–(BUSINESS WIRE)–#biotechshowcase–As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year, the event continued to distinguish itself as a leading hub for early-stage biotechnology companies seeking meaningful visibility, strategic dialogue, and access to private investment. Held alongside the J.P. Morgan Healthcare Conference, Biotech Showcase facilitated 6,000 partnering and investment meetings, complemented by more … [Read more…]

Visit Vektor Medical at Booth 208 to Learn More about vMap®, the VITAL-EP Registry’s AF Findings, and the Newly Released Atrial Flutter Workflow BOSTON–(BUSINESS WIRE)–#AFSymposium2026—Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced its participation in AF Symposium 2026, taking place February 5–8 in Boston, where new clinical data and physician experiences … [Read more…]

SAN SEBASTIAN, Spain–(BUSINESS WIRE)–#HPC–Quantum Motion today announced the opening of its offices in Spain, establishing a permanent base for quantum system development, integration and deployment in the European Union. The new site, which is located in the newly inaugurated nanoGUNE Quantum Tower, supports Quantum Motion’s scale-up of silicon-based quantum computing systems and strengthens the collaboration … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) … [Read more…]

– Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four datasets demonstrating the potential benefits of its investigational therapies for … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general … [Read more…]

NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company’s common stock … [Read more…]

Injunction orders Lexqi to halt U.S. Sales of wearable health tracker BOSTON–(BUSINESS WIRE)–WHOOP, the human performance company, today announced that the U.S. District Court for the District of Massachusetts has granted a motion by WHOOP for a preliminary injunction against Shenzhen Lexqi Electronic Technology Co., Ltd. (Lexqi). The injunction, issued in a trade dress infringement … [Read more…]

PARK CITY, Utah & IRVINE, Calif.–(BUSINESS WIRE)–BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, resulting in the formation of Forma Life Sciences, Inc. (FORMA), a Delaware corporation established to hold and operate the acquired assets. … [Read more…]

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568). CD37 is a transmembrane protein that plays … [Read more…]